by Dr. Barbara Price
Anthrax Vaccination Update
In the continuing unfolding story of the vaccines produced by the Michigan Biological Products Institute, MBPI, there is some disagreement within FDA and DoD as to who is responsible for inspecting the anthrax vaccine line. The FDA has the authority and responsibility for inspecting vaccine production.
However according to the inspection report of the November 1996 FDA inspection at MBPI, the FDA did not cover the anthrax vaccine inspection "since it comes under military inspection." The DoD Health Affairs Office says the FDA inspects the anthrax vaccine line, not the military. But according to Dr. Robert Meyers, COO, the Army does inspect the anthrax vaccine line, but the FDA has not relinquished authority to the DoD.
The FDA inspectors have said that until recently, the anthrax vaccine line was inspected only by the military. The concern has been that if FDA has given an exception to DoD for the anthrax vaccine, is DoD responsible for the safety and efficacy of the vaccine? And if so, the DoD cannot say the FDA has approved the anthrax vaccine. How much distance is the FDA putting between it and the anthrax vaccine? Other reports have said that the DoD owns and maintains the anthrax vaccine line. Who inspects the anthrax vaccines given to veterinarians and meat handlers?
MBPI makes the pertussis vaccine, rabies vaccine and diphtheria, pertussis, tetanus vaccine components, as well as plasma derivatives of albumin and immune globulin. In fact, according to some reports, MBPI is the only source of immune globulin. According to the PRNewswire report announcing the $29 million dollar award to BioPort Corp. for anthrax vaccine production, BioPort expects to earn most of its revenue from the sale of the anthrax vaccines to DoD and from its plasma fractionation services.
Antimicrobial Agent for Anthrax
University of Michigan and Novavax, Inc. of Columbia Maryland have tested a chemical mixture, BCTP, against both anthrax and the flu virus and found it effective. BCTP is an emulsion of water, soybean oil, Triton X 100 and tri-n-butyl phosphate. The BCTP killed most of the anthrax spores (Bacillus anthracis) in a culture dish. BCTP also reduced the mouse death rate to 20%, reduced skin lesions and swelling and helped to heal lesions on mouse skin after it was applied to lesions infected with a relative of anthrax, Bacillus cereus.
In separate experiments, laboratory mice stayed healthy after BCTP, along with influenza A, was inserted into their nasal passages. Between these studies and the development of a vaccine based on protective antigen, it is possible that the "old-fashioned" vaccine produced by BioPort will quickly become obsolete.
Editors Note: Assured Capital Return - to the Max!: In September start-up company BioPort Corp. bought the only US manufacturer of anthrax vaccine, the MBPI for a reported $25 million. This included around $3.25M in cash and the rest in IOUs. Within three weeks, BioPort "won" a Pentagon contract for $29 million to supply anthrax vaccine. Fortune smile$ on the favored few.
|For the Professional in Government and Industry with an interest in Nuclear, Biological and Chemical Defense, Disarmament and Verification; Emergency and Disaster Medical Planning; Industrial Health and Safety; and Environmental Protection|